Preclinical Evaluation of 177Lu-Labeled Anti-CLDN18.2 VHH-Fc for Radioimmunotherapy in Gastric Cancer
Molecular Pharmaceutics · 03.08.2026 · 23 (8) · 4101-4111
DOI: 10.1021/acs.molpharmaceut.6c00113 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 01.07.2026. Verfasst von Xiaoyan Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Peking University Shenzhen Hospital, Shenzhen518036, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Radioimmunotherapy, Lutetium, Immunoconjugates. Die Arbeit nennt 33 Literaturangaben. Gefördert von: Natural Science Foundation of Guangdong Province, Shenzhen High-level Hospital Construction Fund, National Basic Research Program of China (973 Program).
Abstract (Originalsprache)
Purpose
Claudin18.2 (CLDN18.2) has emerged as a significant therapeutic target for advanced gastric cancer. In this study, we aimed to develop a 177Lu-radiolabeled anti-CLDN18.2 VHH-Fc (SN-1A01) for radioimmunotherapy in gastric cancer (GC) tumor-bearing models.
Methods
Immunohistochemistry (IHC) for CLDN18.2 was performed on gastric lesions induced by tumors from 37 patients with GC, as well as in a GC patient-derived xenograft (GC-PDX) tumor and GC xenograft tumors (N87–18.2 and NUCG4). The SN-1A01 was conjugated with DOTA and radiolabeled using 177Lu, resulting in the formation of the radioimmunoconjugate [177Lu]Lu-DOTA–SN–1A01. We established a safe dosage for the application of [177Lu]Lu-DOTA–SN–1A01 and evaluated the therapeutic efficacy of a single dose in GC models. Ki67 expression levels in tumors were detected via IHC following treatment with [177Lu]Lu-DOTA–SN–1A01.
Results
IHC analysis demonstrated moderate-to-high CLDN18.2 expression in 45.9% of GC patient tumor tissues. Additionally, elevated levels of CLDN18.2 were detected in GC-PDX and N87–18.2 tumors, whereas lower expression was shown in NUGC4. A single dose of [177Lu]Lu-DOTA–SN–1A01 below 300 μCi (11.1 MBq) was well tolerated. [177Lu]Lu-DOTA–SN–1A01 significantly inhibited tumor growth and increased survival time in both GC-PDX and N87–18.2 models across a dose of 100 and 300 μCi. However, the tumor-suppressive effect was comparatively weaker in the NUGC4 model. Reduced Ki67 expression was evident in all [177Lu]Lu-DOTA–SN–1A01-treated tumors.
Conclusion
In preclinical studies, [177Lu]Lu-DOTA–SN–1A01 demonstrated significant antitumor efficacy with acceptable toxicity, which indicated a strong potential for clinical translation in GC therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Peking University Shenzhen Hospital, Shenzhen518036, China.
- Department of Pharmacy, Peking University Shenzhen Hospital, Shenzhen518036, China.
- School of Public Health, Shanxi Medical University, Taiyuan030001, China.
- Institute of Biomedical Engineering, Shenzhen Bay Lab, Shenzhen518132, China.
- Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan430022, China.
ORCID-Profile: Dawei Jiang
Förderung
- Natural Science Foundation of Guangdong Province
- Shenzhen High-level Hospital Construction Fund
- National Basic Research Program of China (973 Program)
- National Natural Science Foundation of China (NSFC)
- Shenzhen Science and Technology Innovation Commission
- Peking University Shenzhen Hospital Scientific Research Fund
Zitieren
APA
Wang, X., Chen, P., Li, J., Zhang, R., Yan, H., Li, Z., Huang, Z., Xu, C., Zhang, J., Zhu, W., Peng, Q., Xie, S., Jiang, D., & Dong, M. (2026). Preclinical Evaluation of 177Lu-Labeled Anti-CLDN18.2 VHH-Fc for Radioimmunotherapy in Gastric Cancer. Molecular Pharmaceutics, 23(8), 4101-4111. https://doi.org/10.1021/acs.molpharmaceut.6c00113
Vancouver
Wang X, Chen P, Li J, Zhang R, Yan H, Li Z, et al. Preclinical Evaluation of 177Lu-Labeled Anti-CLDN18.2 VHH-Fc for Radioimmunotherapy in Gastric Cancer. Molecular Pharmaceutics. 2026;23(8):4101-4111. doi:10.1021/acs.molpharmaceut.6c00113
BibTeX
@article{Wang2026,
author = {Wang, Xiaoyan and Chen, Ping and Li, Jun and Zhang, Rui and Yan, Haoyi and Li, Zhan and Huang, Zixuan and Xu, Chuanmian and Zhang, JinYuan and Zhu, Wenjing and Peng, Qiyu and Xie, Siwei and Jiang, Dawei and Dong, Mengjie},
title = {Preclinical Evaluation of 177Lu-Labeled Anti-CLDN18.2 VHH-Fc for Radioimmunotherapy in Gastric Cancer},
journal = {Molecular Pharmaceutics},
year = {2026},
volume = {23},
number = {8},
pages = {4101--4111},
doi = {10.1021/acs.molpharmaceut.6c00113}
}
EUVIMED